Mary T Szela - Net Worth and Insider Trading

Mary T Szela Net Worth

The estimated net worth of Mary T Szela is at least $15 Million dollars as of 2024-10-05. Mary T Szela is the Senior Vice President of Abbott Laboratories and owns about 119,422 shares of Abbott Laboratories (ABT) stock worth over $13 Million. Mary T Szela is the CEO AND PRESIDENT of TriSalus Life Sciences Inc and owns about 384,677 shares of TriSalus Life Sciences Inc (TLSI) stock worth over $2 Million. Mary T Szela is also the Director of Coherus BioSciences Inc and owns about 0 shares of Coherus BioSciences Inc (CHRS) stock worth over $0. Details can be seen in Mary T Szela's Latest Holdings Summary section.

Disclaimer: The insider information is derived from SEC filings. The estimated net worth is based on the final shares held after open market or private purchases and sales of common stock with a transaction code of "P" or "S" on Form 4, assuming that Mary T Szela has not made any transactions after 2024-09-13 and currently still holds the listed stock(s). Please note that this estimate may not reflect the actual net worth.

Transaction Summary of Mary T Szela

Mary T Szela Insider Ownership Reports

Based on ownership reports from SEC filings, as the reporting owner, Mary T Szela owns 10 companies in total, including Kura Oncology Inc (KURA) , Coherus BioSciences Inc (CHRS) , and Alimera Sciences Inc (ALIM) among others .

Click here to see the complete history of Mary T Szela’s form 4 insider trades.

Insider Ownership Summary of Mary T Szela

Ticker	Comapny	Transaction Date	Type of Owner
KURA	Kura Oncology Inc	2018-11-06	director
CHRS	Coherus BioSciences Inc	2020-06-22	director
ALIM	Alimera Sciences Inc	2018-06-19	director
		2017-05-09	director & Chief Executive Officer
		2016-11-29	director & Chief Executive Officer
		2011-12-14	Senior Vice President
		2021-03-11	director
		2021-07-29	director
		2024-09-13	director & CEO and President
		2023-08-10	director & CEO and President

Mary T Szela Latest Holdings Summary

Mary T Szela currently owns a total of 3 stocks. Among these stocks, Mary T Szela owns 119,422 shares of Abbott Laboratories (ABT) as of December 14, 2011, with a value of $13 Million and a weighting of 88.49%. Mary T Szela owns 384,677 shares of TriSalus Life Sciences Inc (TLSI) as of September 13, 2024, with a value of $2 Million and a weighting of 11.51%. Mary T Szela also owns 0 shares of Coherus BioSciences Inc (CHRS) as of June 22, 2020, with a value of $0 and a weighting of 0%.

Latest Holdings of Mary T Szela

Ticker	Comapny	Latest Transaction Date	Shares Owned	Current Price ($)	Current Value ($)
ABT	Abbott Laboratories	2011-12-14	119,422	112.64	13,451,694
TLSI	TriSalus Life Sciences Inc	2024-09-13	384,677	4.55	1,750,280
CHRS	Coherus BioSciences Inc	2020-06-22	0	1.04	0

Holding Weightings of Mary T Szela

Mary T Szela Form 4 Trading Tracker

According to the SEC Form 4 filings, Mary T Szela has made a total of 0 transactions in Abbott Laboratories (ABT) over the past 5 years. The most-recent trade in Abbott Laboratories is the sale of 53,201 shares on December 14, 2011, which brought Mary T Szela around $3 Million.

According to the SEC Form 4 filings, Mary T Szela has made a total of 2 transactions in TriSalus Life Sciences Inc (TLSI) over the past 5 years, including 2 buys and 0 sells. The most-recent trade in TriSalus Life Sciences Inc is the acquisition of 14,815 shares on September 13, 2024, which cost Mary T Szela around $75,408.

According to the SEC Form 4 filings, Mary T Szela has made a total of 1 transactions in Coherus BioSciences Inc (CHRS) over the past 5 years, including 0 buys and 1 sells. The most-recent trade in Coherus BioSciences Inc is the sale of 54,997 shares on June 22, 2020, which brought Mary T Szela around $966,847.

Insider Trading History of Mary T Szela

No transactions are available. GuruFocus only tracks and displays the purchase and sale of non-derivative security in open market or private transactions from SEC filings with the transaction code of P or S.

Total 0

Only the transactions in Open Market or Private Sale at the market prices are included. Other transactions such as conversion of derivative security or exercise of options are not included. Insiders are limited to only officers and/or directors of the company.

Mary T Szela Trading Performance

GuruFocus tracks the stock performance after each of Mary T Szela's buying transactions within different timeframes. To be detailed, the average return of stocks after 3 months bought by Mary T Szela is %. GuruFocus also compares Mary T Szela's trading performance to market benchmark return within the same time period. The performance of stocks bought by Mary T Szela within 3 months outperforms times out of transactions in total compared to the return of S&P 500 within the same period.

You can select different timeframes to see how Mary T Szela's insider trading performs compared to the benchmark.

Please note GuruFocus will not track the insiders’ transaction performance if he/she does not have buying transactions.

Performance of Mary T Szela

Average Return

No transaction record over 1 Year.

Outperforming Transactions

No transaction record over 1 Year.

Each transaction is measured over a period and compared to .

	1 Month	3 Months	6 Months	1 Year	2 Years	3 Years
Return(%)	-4.08
Relative Return to S&P 500(%)	-7.52

Mary T Szela Ownership Network

Ownership Network List of Mary T Szela

No Data

Ownership Network Relation of Mary T Szela

Mary T Szela Owned Company Details

What does Kura Oncology Inc do?

Who are the key executives at Kura Oncology Inc?

Mary T Szela is the director of Kura Oncology Inc. Other key executives at Kura Oncology Inc include Chief Legal Officer Teresa Brophy Bair , Chief Medical Officer Stephen Dale , and SVP & Finance & Accounting Thomas James Doyle .

Kura Oncology Inc (KURA) Insider Trades Summary

Over the past 18 months, Mary T Szela made no insider transaction in Kura Oncology Inc (KURA). Other recent insider transactions involving Kura Oncology Inc (KURA) include a net sale of 4,668 shares made by Teresa Brophy Bair , a net sale of 91,052 shares made by Troy Edward Wilson , and a net purchase of 50,000 shares made by Thomas Malley .

In summary, during the past 3 months, insiders sold 0 shares of Kura Oncology Inc (KURA) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 111,517 shares of Kura Oncology Inc (KURA) were sold and 50,000 shares were bought by its insiders, resulting in a net sale of 61,517 shares.

Kura Oncology Inc (KURA)'s detailed insider trading history can be found in Insider Trading Tracker table.

Kura Oncology Inc Insider Transactions

No Available Data

What does Coherus BioSciences Inc do?

Who are the key executives at Coherus BioSciences Inc?

Mary T Szela is the director of Coherus BioSciences Inc. Other key executives at Coherus BioSciences Inc include director & President and CEO Dennis M Lanfear , Chief Financial Officer Mcdavid Stilwell , and See Remarks Bryan J Mcmichael .

Coherus BioSciences Inc (CHRS) Insider Trades Summary

Over the past 18 months, Mary T Szela made no insider transaction in Coherus BioSciences Inc (CHRS). Other recent insider transactions involving Coherus BioSciences Inc (CHRS) include a net sale of 223,100 shares made by Dennis M Lanfear ,

In summary, during the past 3 months, insiders sold 0 shares of Coherus BioSciences Inc (CHRS) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 223,100 shares of Coherus BioSciences Inc (CHRS) were sold and 0 shares were bought by its insiders, resulting in a net sale of 223,100 shares.

Coherus BioSciences Inc (CHRS)'s detailed insider trading history can be found in Insider Trading Tracker table.

Coherus BioSciences Inc Insider Transactions

No Available Data

What does Alimera Sciences Inc do?

Who are the key executives at Alimera Sciences Inc?

Mary T Szela is the director of Alimera Sciences Inc. Other key executives at Alimera Sciences Inc include 10 percent owner Caligan Partners Lp , other: Chairman Emeritus C. Daniel Myers , and 10 percent owner David Edward Johnson .

Alimera Sciences Inc (ALIM) Insider Trades Summary

Over the past 18 months, Mary T Szela made no insider transaction in Alimera Sciences Inc (ALIM). Other recent insider transactions involving Alimera Sciences Inc (ALIM) include a net sale of 0 shares made by Caligan Partners Lp , and a net purchase of 1,401,901 shares made by Adam Morgan .

In summary, during the past 3 months, insiders sold 0 shares of Alimera Sciences Inc (ALIM) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 579,000 shares of Alimera Sciences Inc (ALIM) were sold and 1,980,901 shares were bought by its insiders, resulting in a net purchase of 1,401,901 shares.

Alimera Sciences Inc (ALIM)'s detailed insider trading history can be found in Insider Trading Tracker table.

Alimera Sciences Inc Insider Transactions

No Available Data

What does Novelion Therapeutics Inc do?

Who are the key executives at Novelion Therapeutics Inc?

Mary T Szela is the director & Chief Executive Officer of Novelion Therapeutics Inc. Other key executives at Novelion Therapeutics Inc include 10 percent owner Broadfin Healthcare Master Fund Ltd , 10 percent owner Broadfin Capital, Llc , and 10 percent owner Kevin Kotler .

Novelion Therapeutics Inc (NVLNF) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of Novelion Therapeutics Inc (NVLNF) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Novelion Therapeutics Inc (NVLNF) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

Novelion Therapeutics Inc (NVLNF)'s detailed insider trading history can be found in Insider Trading Tracker table.

Novelion Therapeutics Inc Insider Transactions

No Available Data

What does Aegerion Pharmaceuticals Inc do?

Who are the key executives at Aegerion Pharmaceuticals Inc?

Mary T Szela is the director & Chief Executive Officer of Aegerion Pharmaceuticals Inc. Other key executives at Aegerion Pharmaceuticals Inc include other: See Remarks Gregory D Perry , General Counsel and Secretary Benjamin Harshbarger , and 10 percent owner Broadfin Healthcare Master Fund Ltd .

Aegerion Pharmaceuticals Inc (AEGR) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of Aegerion Pharmaceuticals Inc (AEGR) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Aegerion Pharmaceuticals Inc (AEGR) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

Aegerion Pharmaceuticals Inc (AEGR)'s detailed insider trading history can be found in Insider Trading Tracker table.

Aegerion Pharmaceuticals Inc Insider Transactions

No Available Data

What does Abbott Laboratories do?

Who are the key executives at Abbott Laboratories?

Mary T Szela is the Senior Vice President of Abbott Laboratories. Other key executives at Abbott Laboratories include Senior Vice President Robert B Ford , VICE PRESIDENT Mccoy John A. Jr. , and Vice President & Controller Robert E Funck .

Abbott Laboratories (ABT) Insider Trades Summary

Over the past 18 months, Mary T Szela made no insider transaction in Abbott Laboratories (ABT). Other recent insider transactions involving Abbott Laboratories (ABT) include a net sale of 88,626 shares made by Andrea F Wainer , a net sale of 150,000 shares made by Daniel J Starks , and a net sale of 23,546 shares made by Lisa D Earnhardt .

In summary, during the past 3 months, insiders sold 141,706 shares of Abbott Laboratories (ABT) in total and bought 0 shares, with a net sale of 141,706 shares. During the past 18 months, 425,740 shares of Abbott Laboratories (ABT) were sold and 0 shares were bought by its insiders, resulting in a net sale of 425,740 shares.

Abbott Laboratories (ABT)'s detailed insider trading history can be found in Insider Trading Tracker table.

Abbott Laboratories Insider Transactions

No Available Data

What does Prometheus Biosciences Inc do?

Who are the key executives at Prometheus Biosciences Inc?

Mary T Szela is the director of Prometheus Biosciences Inc. Other key executives at Prometheus Biosciences Inc include Chief Financial Officer Keith W Marshall , director & President and CEO Mark C. Mckenna , and 10 percent owner Cedars Sinai Intellectual Property Co .

Prometheus Biosciences Inc (RXDX) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of Prometheus Biosciences Inc (RXDX) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Prometheus Biosciences Inc (RXDX) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

Prometheus Biosciences Inc (RXDX)'s detailed insider trading history can be found in Insider Trading Tracker table.

Prometheus Biosciences Inc Insider Transactions

No Available Data

What does Omega Therapeutics Inc do?

Who are the key executives at Omega Therapeutics Inc?

Mary T Szela is the director of Omega Therapeutics Inc. Other key executives at Omega Therapeutics Inc include director & 10 percent owner Richard A Young , 10 percent owner Flagship Pioneering Fund Vii General Partner Llc , and 10 percent owner Flagship Pioneering Fund Vii, L.p. .

Omega Therapeutics Inc (OMGA) Insider Trades Summary

Over the past 18 months, Mary T Szela made no insider transaction in Omega Therapeutics Inc (OMGA). Other recent insider transactions involving Omega Therapeutics Inc (OMGA) include a net sale of 10,000 shares made by Richard A Young ,

In summary, during the past 3 months, insiders sold 0 shares of Omega Therapeutics Inc (OMGA) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 10,000 shares of Omega Therapeutics Inc (OMGA) were sold and 0 shares were bought by its insiders, resulting in a net sale of 10,000 shares.

Omega Therapeutics Inc (OMGA)'s detailed insider trading history can be found in Insider Trading Tracker table.

Omega Therapeutics Inc Insider Transactions

No Available Data

What does TriSalus Life Sciences Inc do?

Who are the key executives at TriSalus Life Sciences Inc?

Mary T Szela is the director & CEO and President of TriSalus Life Sciences Inc. Other key executives at TriSalus Life Sciences Inc include President & Therapeutics Jodi Devlin , director & 10 percent owner Mats Wahlstrom , and 10 percent owner Equity Ab Frankenius .

TriSalus Life Sciences Inc (TLSI) Insider Trades Summary

Over the past 18 months, Mary T Szela made 2 insider transaction in TriSalus Life Sciences Inc (TLSI) with a net purchase of 19,815. Other recent insider transactions involving TriSalus Life Sciences Inc (TLSI) include a net sale of 9 shares made by George Kelly Martin ,

In summary, during the past 3 months, insiders sold 9 shares of TriSalus Life Sciences Inc (TLSI) in total and bought 19,815 shares, with a net purchase of 19,806 shares. During the past 18 months, 9 shares of TriSalus Life Sciences Inc (TLSI) were sold and 19,815 shares were bought by its insiders, resulting in a net purchase of 19,806 shares.

TriSalus Life Sciences Inc (TLSI)'s detailed insider trading history can be found in Insider Trading Tracker table.

TriSalus Life Sciences Inc Insider Transactions

No Available Data

What does MedTech Acquisition Corp do?

Who are the key executives at MedTech Acquisition Corp?

Mary T Szela is the director & CEO and President of MedTech Acquisition Corp. Other key executives at MedTech Acquisition Corp include President & Therapeutics Jodi Devlin , director & 10 percent owner Mats Wahlstrom , and 10 percent owner Equity Ab Frankenius .

MedTech Acquisition Corp (MTAC) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of MedTech Acquisition Corp (MTAC) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of MedTech Acquisition Corp (MTAC) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

MedTech Acquisition Corp (MTAC)'s detailed insider trading history can be found in Insider Trading Tracker table.

MedTech Acquisition Corp Insider Transactions

No Available Data

Mary T Szela Mailing Address

Above is the net worth, insider trading, and ownership report for Mary T Szela. You might contact Mary T Szela via mailing address: 10835 Road To The Cure, Suite 205, San Diego Ca 92121.

Discussions on Mary T Szela

No discussions yet.

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Mobile App 中文

Education

Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Site Map Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.